Scinai Immunotherapeutics Restructures $29M Debt to Equity
Ticker: SCNI · Form: 6-K · Filed: Aug 21, 2024 · CIK: 1611747
| Field | Detail |
|---|---|
| Company | Scinai Immunotherapeutics Ltd. (SCNI) |
| Form Type | 6-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $29 million, $273,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-restructuring, equity, financing
TL;DR
Scinai just turned $29M debt into preferred equity with EIB, slashing its debt load.
AI Summary
On August 21, 2024, Scinai Immunotherapeutics Ltd. announced the closing of a Loan Restructuring Agreement with the European Investment Bank. This agreement converts approximately $29 million of debt into preferred equity, leaving a remaining debt balance.
Why It Matters
This restructuring significantly reduces Scinai's debt burden, potentially improving its financial flexibility and attractiveness to investors.
Risk Assessment
Risk Level: medium — While debt reduction is positive, the conversion to preferred equity may dilute existing shareholders and the remaining debt still needs to be managed.
Key Numbers
- $29 million — Debt Restructured (Amount of debt converted to preferred equity)
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant
- European Investment Bank (company) — Lender in loan restructuring
- $29 million (dollar_amount) — Amount of debt converted to equity
- August 21, 2024 (date) — Date of announcement
FAQ
What is the remaining debt balance after the restructuring?
The filing states that approximately $29 million of debt was converted, leaving a debt balance, but the exact remaining amount is not specified in this 6-K.
What are the terms of the preferred equity issued?
The filing does not detail the specific terms, rights, or dividend policies associated with the preferred equity issued to the European Investment Bank.
What is the rationale behind converting debt to preferred equity?
The rationale is to reduce the company's debt obligations and improve its financial structure, as indicated by the reduction in debt balance.
When did Scinai Immunotherapeutics Ltd. change its name from BiondVax Pharmaceuticals Ltd.?
Scinai Immunotherapeutics Ltd. changed its name from BiondVax Pharmaceuticals Ltd. on June 24, 2014.
What is the primary business of Scinai Immunotherapeutics Ltd.?
Scinai Immunotherapeutics Ltd. is involved in Biological Products (excluding diagnostic substances), as indicated by its SIC code [2836].
Filing Stats: 269 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-21 09:10:49
Key Financial Figures
- $29 million — nvestment Bank converting approximately $29 million of debt to preferred equity and leaving
- $273,000 — ed equity and leaving a debt balance of $273,000. A copy of the press release is furni
Filing Documents
- ea0212017-6k_scinai.htm (6-K) — 12KB
- ea021201701ex99-1_scinai.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 13KB
- 0001213900-24-071280.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: August 21, 2024 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2